You are here

Solid Biosciences

Solid Bio hopes to fortify itself after fusing with AavantiBio, but not before axing its lead asset

Solid Bio hopes to fortify itself after fusing with AavantiBio, but not before axing its lead asset

Fierce Biotech

Solid Biosciences

Flag link:

Pfizer, Sarepta team with fellow DMD gene therapy makers to get to the bottom of adverse events

Pfizer, Sarepta team with fellow DMD gene therapy makers to get to the bottom of adverse events

Fierce Biotech

Duchenne Muscular Dystrophy

Sarepta Therapeutics

Solid Biosciences

Flag link:

Solid Bio’s long, troubled slog through the clinic yields promising early data. Can it win back trust?

Solid Bio’s long, troubled slog through the clinic yields promising early data. Can it win back trust?

Endpoints

Solid Biosciences

Duchenne Muscular Dystrophy

Flag link:

FDA Lifts Clinical Hold on Solid Biosciences’ DMD Gene Therapy Trial

FDA Lifts Clinical Hold on Solid Biosciences’ DMD Gene Therapy Trial

BioSpace

Solid Biosciences

clinical trials

Duchenne Muscular Dystrophy

Flag link:

FDA keeps Solid Bio's troubled Duchenne MD gene therapy on clinical lockdown in latest setback

FDA keeps Solid Bio's troubled Duchenne MD gene therapy on clinical lockdown in latest setback

Endpoints

Solid Biosciences

Duchenne Muscular Dystrophy

Flag link:

Solid Bio Restructures to Get Halted Gene Therapy Study Back on Track

Solid Bio Restructures to Get Halted Gene Therapy Study Back on Track

Xconomy

Solid Biosciences

Duchenne Muscular Dystrophy

Flag link:

3 Biotech Stocks With Big Incoming Catalysts

3 Biotech Stocks With Big Incoming Catalysts

Motley Fool

Axsome Therapeutics

Solid Biosciences

Duchenne Muscular Dystrophy

major depressive disorder

Intra-Cellular Therapies

Flag link:

Solid Biosciences’ Duchenne gene therapy trial halted after patient suffers serious toxicity

Solid Biosciences’ Duchenne gene therapy trial halted after patient suffers serious toxicity

Stat

Solid Biosciences

Duchenne Muscular Dystrophy

clinical trials

Flag link:

Solid Biosciences Surges on DMD Gene Therapy Study Amendments

Solid Biosciences Surges on DMD Gene Therapy Study Amendments

Yahoo/Zacks.com

Solid Biosciences

Duchenne Muscular Dystrophy

Flag link:

Solid Biosciences’ Duchenne Muscular Dystrophy Drug Has Side Effect Issues

Solid Biosciences’ Duchenne Muscular Dystrophy Drug Has Side Effect Issues

BioSpace

Solid Biosciences

Duchenne Muscular Dystrophy

Flag link:

Solid Bio is hit by another setback as initial biopsies spotlight a flop for Duchenne MD

Solid Bio is hit by another setback as initial biopsies spotlight a flop for Duchenne MD

Endpoints

Solid Biosciences

clinical trials

Duchenne Muscular Dystrophy

Flag link:

3 Best Gene Therapy Stocks of 2018 (So Far)

3 Best Gene Therapy Stocks of 2018 (So Far)

Motley Fool

Sarepta Therapeutics

Solid Biosciences

Flag link:

As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy

As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy

Xconomy

Duchenne Muscular Dystrophy

Solid Biosciences

Sarepta Therapeutics

Flag link:

Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)

Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)

CP Wire

Solid Biosciences

Duchenne Muscular Dystrophy

clinical trials

Flag link:

Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)

Solid Biosciences

Duchenne Muscular Dystrophy

Flag link:

Solid Bio's DMD gene therapy graduates from partial FDA hold to full-on clinical hold

Solid Bio's DMD gene therapy graduates from partial FDA hold to full-on clinical hold

Fierce Biotech

Solid Biosciences

Duchenne Muscular Dystrophy

Flag link:

In an end-of-year IPO blitz, 4 biotechs pitch new offerings totaling $370M

In an end-of-year IPO blitz, 4 biotechs pitch new offerings totaling $370M

Endpoints

ARMO BioSciences

Menlo Therapeutics

Solid Biosciences

Flag link:

How the newest Duchenne biotechs are getting a boost from patient groups

How the newest Duchenne biotechs are getting a boost from patient groups

Bizjournals.com

Duchenne Muscular Dystrophy

Sarepta Therapeutics

Akashi Therapeutics

Summit Therapeutics

Solid Biosciences

Flag link: